Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03834623 · ClinicalTrials.gov registry record · Phase 2
Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03834623 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 23 participants.
The verdict
NCT03834623, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune response).
Interventions
- DRUG Nivolumab
- DRUG CC-122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-05-14 |
| Est. Completion | 2021-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03834623
The ClinicalTrials.gov registry entry for NCT03834623 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03834623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03834623 about?
NCT03834623 is a clinical study titled "Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma". This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune response).
What is the current status of trial NCT03834623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2019-05-14. Estimated completion is 2021-08-04.
What interventions are being tested in trial NCT03834623?
The interventions under investigation include: Nivolumab (DRUG), CC-122 (DRUG).
Who is sponsoring clinical trial NCT03834623?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.